Publikationsdatenbank

GrimACE:
automated, multimodal cage-side assessment of pain and well-being in mice (2025)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Sturman, Oliver

Schmutz, Marcel

Lorimer, Tom

Zhang, Runzhong

Privitera, Mattia

Roessler, Fabienne

Leonardi, Justine

Waag, Rebecca

Marinescu, Alina-Mariuca

Bekemeier, Clara (WE 11)

Hohlbaum, Katharina

Bohacek, Johannes

Quelle

bioRxiv beta : the preprint server for biology

Seiten: 1

ISSN: 2692-8205

Sprache

Englisch

Verweise

URL (Volltext): https://www.biorxiv.org/content/10.1101/2025.03.07.642046v1

DOI: 10.1101/2025.03.07.642046

Kontakt

Institut für Tierschutz, Tierverhalten und Versuchstierkunde

Königsweg 67
14163 Berlin
+49 30 838 61146
tierschutz@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Pain and welfare monitoring is essential for ethical animal testing, but current cage-side assessments are qualitative and subjective. Here we present the GrimACE, the first fully standardised and automated cage-side monitoring tool for mice, the most widely used animals in research. The GrimACE uses computer vision to provide automated mouse grimace scale (MGS) assessment together with pose estimation in a dark, safe environment. We validated the system by analysing pain after brain surgeries (craniotomies) with head implants under two analgesia regimes. Human-expert and automated MGS scores showed very high correlation (Pearson’s r=0.87). Both expert and automated scores revealed that a moderate increase in pain can be detected for up to 48 hours after surgeries, but that both a single dose of meloxicam (5mg/kg s.c.) or 3 doses of buprenorphine (0.1mg/kg) + meloxicam (5mg/kg s.c.) provide adequate and comparable pain management. Simultaneous pose estimation demonstrated that mice receiving buprenorphine + meloxicam showed increased movement 4h after surgery, indicative of hyperactivity, a well-known side-effect of opioid treatment. Significant weight loss was also detected in the buprenorphine + meloxicam treatment group compared to the meloxicam-only group. Additionally, detailed BehaviorFlow analysis and automated MGS scoring of control animals suggests that habituation to the GrimACE system is unnecessary, and that measurements can be repeated multiple times, ensuring standardised post-operative recovery monitoring.